How to Lose Fat: Peptides, Supplements & Biomarkers Guide

The short version

Sustainable fat loss in 2026 is a metabolic intervention, not a willpower test. The compounds that actually move the needle - semaglutide, tirzepatide, retatrutide - work by recalibrating insulin sensitivity, satiety, and inflammation. The supplements that pair with them prevent the muscle loss and nutrient deficiencies that derail most cuts. The biomarkers tell you whether the protocol is producing real metabolic improvement or just scale movement.

Why this protocol works

GLP-1 receptor agonists drove a 15–22% body-weight reduction across the STEP and SURMOUNT trials, but the published data also showed 25–40% of weight lost was lean mass in participants without structured resistance training and adequate protein. Pairing the medication with a recovery-supportive supplement stack - magnesium, B12, fish oil, electrolytes - addresses the most-cited deficiencies that show up after 3–6 months on these compounds.

The biomarkers that matter for fat loss are NOT body weight or BMI - those move for the wrong reasons (water, muscle). ApoB shows whether your cardiovascular risk is improving. HbA1c shows whether insulin sensitivity is recovering. Liver enzymes show whether visceral fat is resolving. Fasting insulin shows the recovery curve faster than HbA1c.

Deep Dive

Fat loss is a hormonal event, not just a calorie subtraction

The body actively defends its fat mass. Adipose tissue is an endocrine organ that secretes leptin, adiponectin, and inflammatory signaling molecules, and it runs a feedback loop with the hypothalamus that governs hunger and energy expenditure. This is why "eat less, move more" so often stalls on its own: as fat mass falls, leptin drops and ghrelin rises, and the brain reads the deficit as a threat to be corrected.

A second distinction matters more than total weight: **visceral fat versus subcutaneous fat**. Visceral adipose tissue packed around the organs drains into the portal vein and delivers free fatty acids and inflammatory cytokines directly to the liver, which is why it is far more strongly associated with insulin resistance, elevated triglycerides, and cardiovascular risk than the subcutaneous fat under the skin. Two people at the same weight can carry very different metabolic risk depending on where the fat sits. It is also why the scale is a weak instrument on its own: it cannot separate visceral fat from subcutaneous fat, water, or muscle.

Reading the biomarkers - what a working protocol looks like on paper

Beyond the standard panel, a few derived and adjunct markers add signal and are commonly tracked:

- **Waist-to-height ratio** is a simple visceral-adiposity proxy. A ratio under 0.5 (waist less than half your height) is the threshold cited in guidance such as the UK NICE recommendations, and it maps to metabolic risk better than BMI because it ignores muscle. - **Triglyceride-to-HDL ratio** is commonly tracked as a surrogate for insulin resistance. A falling ratio usually moves in step with recovering insulin sensitivity, often before HbA1c shifts. - **ALT and GGT** reflect liver fat. Elevated liver enzymes are associated with excess hepatic fat, and a decline as fat loss proceeds is one of the earliest signs that visceral and liver fat are coming down. - **hs-CRP** captures the low-grade inflammation that adipose tissue drives. It is associated with cardiometabolic risk and tends to fall as fat mass and inflammatory signaling decrease.

Read these as a trend across baseline, 12 weeks, and 6 months rather than single snapshots, and discuss interpretation with a licensed clinician.

How the incretin compounds actually work

The compounds driving modern fat-loss results are incretin-based. Incretins are gut hormones - GLP-1 is released by intestinal L-cells and GIP by K-cells - that signal in response to eating.

- **Semaglutide** is a GLP-1 receptor agonist. Research indicates it works through several routes at once: slowing gastric emptying so meals feel filling for longer, enhancing glucose-dependent insulin secretion, and acting on appetite-regulating neurons in the hypothalamic arcuate nucleus to reduce hunger and food reward. - **Tirzepatide** is a dual GIP and GLP-1 receptor agonist, sometimes called a "twincretin." Adding GIP activity appears to influence both appetite and insulin sensitivity beyond GLP-1 alone, though the exact contribution of GIP is still an active research question. - **Retatrutide** is an investigational triple agonist targeting GLP-1, GIP, and the glucagon receptor. The glucagon component is the notable addition because glucagon receptor activity is associated with increased energy expenditure and hepatic fat mobilization, on top of the appetite effects. - **AOD-9604** is a synthetic fragment of the C-terminal region of human growth hormone that is often marketed for fat loss. The human clinical evidence is limited, and the controlled testing that has been done did not show weight loss beyond placebo, so its fat-loss evidence is weak relative to the incretins.

None of this is medical advice, and these compounds carry side-effect and eligibility considerations that belong in a conversation with a licensed clinician.

What the trials actually show about timelines

The published data is unusually clear about both magnitude and pace:

- In **STEP 1** (Wilding et al., NEJM 2021), semaglutide 2.4 mg weekly produced a mean weight reduction of about 14.9% over 68 weeks. - In **SURMOUNT-1** (Jastreboff et al., NEJM 2022), tirzepatide reached about 20.9% at the 15 mg dose over 72 weeks. - In a **phase 2 retatrutide** trial (Jastreboff et al., NEJM 2023), the 12 mg dose reached roughly 24% at 48 weeks, still investigational.

Two patterns matter for expectations. First, the curve is not linear: most of the loss happens in the first several months and flattens toward a plateau around week 60 to 68. Second, and most misunderstood, the effect depends on continued use. In the STEP 1 extension (Wilding et al., 2022), participants regained about two-thirds of the lost weight within a year of stopping, because the underlying appetite and energy-expenditure signaling reverts. Separately, the **SELECT** trial (Lincoff et al., NEJM 2023) found semaglutide was associated with roughly a 20% reduction in major cardiovascular events in people with overweight or obesity and established cardiovascular disease, a benefit associated with more than the number on the scale.

Metabolic adaptation and the mistakes that stall progress

The most under-appreciated force is **adaptive thermogenesis**: as you lose weight, resting energy expenditure falls by more than body-size changes alone predict. The long follow-up of The Biggest Loser participants (Fothergill et al., Obesity 2016) found this metabolic adaptation persisted for years. Practically, the deficit that worked at the start stops working over time, and aggressive under-eating makes it worse by accelerating lean-mass loss.

The recurring mistakes that flow from ignoring this:

- Treating the intervention as a short-term sprint. The trial data frames sustained fat loss as ongoing metabolic support, so it helps to plan around the plateau and the regain risk rather than be surprised by them. - Reading a stalled scale as failure during recomposition, when waist and body-composition measures are still improving. - Under-eating so severely that lean mass and resting metabolism decline together, which is especially risky for older adults, where losing muscle alongside fat is associated with sarcopenic obesity.

Track the trend, protect muscle, and read the biomarkers - not the scale - as the scoreboard, in partnership with a licensed clinician.

Peptides commonly used for lose fat

Supplement stack pairing

Biomarkers to track for lose fat

The protocol

1. 1
   Pull a baseline panel BEFORE starting: fasting insulin, HbA1c, full lipid panel including ApoB, hs-CRP, liver enzymes (ALT/AST/GGT). Without baseline, you cannot prove the protocol worked.
2. 2
   Start with the lowest medication titration step. GI side effects are dose-dependent and most users underestimate the slow ramp the trials used.
3. 3
   Eat protein. Target ≥1g/kg bodyweight (research-cited threshold for muscle preservation during caloric restriction). Most users on GLP-1 dramatically under-eat protein because total appetite is suppressed.
4. 4
   Resistance train 2–3x/week. Lean mass loss is not inevitable; the trials that combined GLP-1 with structured training showed roughly half the lean mass loss.
5. 5
   Re-test labs at 12 weeks. ApoB and HbA1c should both be moving down. Liver enzymes should be falling. If they are not, the protocol needs adjustment with your provider.

Common pitfalls

• ×Skipping baseline labs - without them, every "is it working?"question is a guess.
• ×Ignoring electrolytes. GLP-1 medications + reduced food = real sodium/magnesium loss. Cramping, headaches, and fatigue are usually electrolyte issues, not the medication.
• ×Not tracking ApoB. Standard lipid panels include LDL-C, which can read normal while ApoB is still elevated. ApoB is the better cardiovascular risk marker - order it specifically.
• ×Tracking weight daily. Water weight masks fat loss for weeks at a time. Weekly average + body composition checks every 4–6 weeks gives a clearer signal.

Frequently Asked Questions

Other goals